Remarks: 1. ORA districts/divisions should use this revised compliance program (7346.832-Preapproval Inspections) for preapproval inspections (PAIs) of manufacturing facilities in support of pending drug applications. 3 2. Under this compliance program, ORA preapproval program managers (PAMs) are responsible for reporting inspectional results. ORA's Office of Pharmaceutical Quality Operations, in its Office of Medical Products and Tobacco Operations, maintains a list of ORA PAMs (including 1 See https://www.fda.gov/drugs/pharmaceutical-quality-resources/integration-fda-facility-evaluation-and-inspectionprogram-human-drugs-concept-operations. 2 NDA=new drug application; PEPFAR=President's Emergency Plan for AIDS Relief; CMC=chemistry, manufacturing, and controls; PET=positron emission tomography; ANDA=abbreviated new drug application. 3 In this compliance program, previously identified as a compliance program guidance manual, the terms facility, firm, and establishment are synonymous; manufacturer can differ from these three terms depending on context. PROGRAM 7346.832
• The ORA PAM summarizes the rationale for the recommendation using the comments field or associated dropdown selections in Panorama.
• The ORA PAM recommends approve in Panorama when none of the criteria for withholding apply (see Part V in this compliance program). The ORA PAM recommends withhold in Panorama when there are significant findings (see Part V) or when there is information that, in the ORA division's judgment, warrants further evaluation by CDER before recommending approval of the application.
o When ORA finds that the "establishment is not doing the function it is responsible for as stated in the application" or the "establishment is not ready for inspection," the ORA PAM submits the written documentation that was obtained by the investigator or received from a responsible official at the establishment to support a withhold recommendation.
• For a withhold recommendation, the ORA PAM:
o Emails 3 o Enters appropriate updates into Panorama if follow-up activities have changed the withhold recommendation (i.e., the Form FDA 483 response is found to be adequate or a follow-up PAI is performed).
Facility Alerts
• Do not enter a pOAI alert in Panorama solely because of violative PAI coverage under compliance program 7346.832 during which no marketed product was covered.
• If marketed products are also covered under compliance program 7356.002, and the surveillance part of the inspection is likely to result in an official action indicated (OAI) status, enter a pOAI alert into Panorama, as soon as practical, as described in the Field Reporting Requirements section of compliance program 7356.002.
Firm Profile Class Code Updates
In general, ORA manages the status (acceptable or unacceptable) of profile class codes covered during establishment inspections in accordance with Exhibit 5-14.6.3, Pre-Approval Inspections, in the IOM.
• Profiles are not updated for product-specific PAIs (no CGMP surveillance inspection (compliance program 7356.002) conducted) unless the PAI covers a new profile.
• For a PAI of an establishment with a new profile, the new profile can be added and made acceptable if the inspection is classified as no action indicated (NAI) or voluntary action indicated (VAI) and an approve recommendation for the application is made.
• If an initial PAI of a new profile results in a withhold recommendation (the establishment inspection is classified as OAI), ORA does not enter profile information. This ensures the product cannot be marketed in the United States until a follow-up inspection verifies implementation of appropriate corrective actions or until corrections are substantially verified through other appropriate means.
Sample-Related Reporting Requirements
The Division of Pharmaceutical Analysis in OPQ's Office of Testing and Research (OPQ/OTR/DPA) as well as ORA laboratories perform testing on samples collected (method verification 9 and profile).
If an official sample is collected at an establishment, the investigator should use the appropriate product/assignment codes (PACs) for method verification or profile analyses.
The analyzing laboratory (OPQ/OTR/DPA or ORA/Office of Regulatory Science (ORS)) maintains completed analytical worksheets. OPQ/OTR/DPA enters the laboratory results for method verification samples for a new drug application (NDA) or abbreviated new drug application (ANDA) into Panorama. The analyzing laboratory forwards a copy of the laboratory results to the CDER or ORA office that requested or collected samples. The analyzing laboratory reports adverse findings by emailing a copy of the worksheet to the following recipients:
• The ORA home division of the manufacturer, if applicable.
• The OPQ drug substance assessor or drug product assessor assigned to the submission. 
PART I-BACKGROUND
The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides that FDA may approve a new drug application (NDA) or an abbreviated new drug application (ANDA) if, among other requirements, the methods used in, and the facilities and controls used for, the manufacture, processing, packing, and testing of the drug are found adequate to ensure and preserve its identity, strength, quality, and purity. 10
In 2002, FDA announced a significant initiative called Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century to enhance and modernize the regulation of pharmaceutical manufacturing and product quality. 11 This initiative, now called Pharmaceutical Quality for the 21st Century, encourages implementation of risk-and science-based approaches that focus FDA attention on critical areas to promote better and more consistent decisions among regulators. In accordance with the initiative, this compliance program includes scientific, risk-based approaches that incorporate inspection of the firm, including an assessment of process and product understanding and an evaluation of the firm's manufacturing readiness, its conformance with application commitments, and the reliability of data generated at the site. 
PART II-IMPLEMENTATION

Scope
Preapproval facility evaluations and inspections support the assessment of marketing applications by ensuring that any establishment named in or referenced in support of an application can perform the proposed manufacturing operations in conformance with CGMP requirements and that data submitted in the application are accurate and complete.
• Preapproval facility evaluation: CDER, with ORA participation, considers information about each facility named in a marketing application, the drug being manufactured, and other information in the application to determine whether a preapproval inspection (PAI) is needed before the application can be approved from a quality perspective.
• Preapproval inspection: ORA, with CDER participation, evaluates the adequacy of the manufacturing processes and control strategy to ensure commercial product quality and conformance to application, facility, and CGMP requirements. CDER uses information from the inspection in conjunction with other information to determine whether to approve a drug application.
This program also provides risk-based strategies for the scope of inspectional coverage and clarifies roles to establish efficient communication. During the PAI, if necessary (e.g., systemic CGMP deficiencies are discovered), the scope of the inspection can be expanded to add coverage under compliance program 7356.002.
Strategy
A. Risk-Based Determination for PAI
This revised compliance program reinforces FDA's risk-based approach to determine whether inspections are needed using information provided in applications and information FDA may have regarding the facilities. If FDA finds that sufficient information is available, a PAI may not be needed. When a marketing application is submitted, CDER initiates the preapproval facility evaluation by assembling an integrated quality assessment (IQA) team to perform the quality assessment. The IQA team provides patient-focused and risk-based quality recommendations relating to the drug product, including recommendations for facilities that manufacture, process, package, or hold and test the drug product 14 or drug substance. 15 The team, led by an application technical lead and managed by a regulatory business project manager, consists of a drug substance assessor, drug product assessor, OPF manufacturing assessor, and ORA representative(s). Additional assessors may be assigned as appropriate.
In performing the quality assessment, the IQA team determines the need for PAIs of facilities listed in the application by assessing:
• Product risk and manufacturing (process and facility) risks.
• The accuracy and reliability of the information provided in the application.
Product knowledge and risk assessments focus on understanding the risks associated with a product's critical quality attributes (CQAs) in the specific product's context of use (e.g., therapeutic index, patient population, clinical benefit)2 0 T .2 0 T Drug product design helps to determine whether the product can meet patients' needs and maintain its intended performance through its proposed shelf life.
Manufacturing process risk assessment focuses on understanding the impact of the process on the product's CQAs. A process is generally considered well-understood and controlled when (1) critical sources of variability are identified and explained, (2) variability is managed by the process at all scales, and (3) process performance and product quality attributes can be adequately and reliably controlled.
Good product and process understanding means that characteristics critical to quality from the patient's perspective have been identified and translated into the product's CQAs and that material attributes and process parameters that affect the CQAs have been identified, characterized, and are controlled.
Manufacturing facility risk assessment focuses on the demonstrated capabilities of the manufacturing or testing facilities and their relevance to the marketing application. It includes, but is not limited to, reviews of the facility's recent manufacturing history through the evaluation of establishment inspection reports (EIRs) and exhibits, applicable field alert reports (FARs), associated recalls, regulatory/advisory actions, and available foreign regulatory reports. Site dossiers and responses to requests under section 704(a)(4)(A) of the FD&C Act may provide needed information to conduct a facility risk assessment.
The assessment of the accuracy and integrity of the information from a site, in support of the application, is also an important factor in determining the need for a PAI. A PAI can be triggered when there is a need to confirm the accuracy and reliability of the quality data, which is critical in determining the safety, efficacy, and quality of the drug product. Additionally, a PAI can be triggered to confirm that a facility's operations match those proposed in the application.
In conclusion, the IQA team determines the need for PAIs based on the cumulative risk assessment of the application.
B. Inspection by Objective
There are three primary inspectional objectives for PAIs, each of which requires strategies that consider the concerns and potential risks identified during the IQA team's application assessment and facility risk assessment: PAI coverage is based on specific responsibilities performed at the establishment as well as comparisons between the product and process-specific profile classes, operations, and previously inspected operations for the same establishment. For further details on inspectional and auditing techniques related to these objectives, refer to Part III-Inspectional-of this compliance program. At least one objective must be addressed during the PAI. If significant issues are observed during the PAI, this program allows for adjustments to the inspectional strategy (e.g., expanding the PAI coverage to add coverage under compliance program 7356.002).
Program Management Instructions
A. NDA/ANDA Facility Evaluation and Inspection
Within 60 calendar days 16 of receiving an NDA or ANDA, the Office of Process and Facilities (OPF) sends a PAI or district file review (DFR) request to ORA or enters a facility recommendation via Panorama.
For PAI requests:
• OPF requests the PAI through the OPF Decision/Request task with clear justification and provides specific information on the inspectional strategy regarding the risk and concerns identified.
• ORA evaluates the request, schedules the inspection, and notifies OPF. To the extent possible, ORA and CDER collaborate on the planning and timing of application assessment and inspectional activities. If ORA's evaluation suggests that a PAI is not warranted, a final determination is made in collaboration with OPF. Within 10 business days of receiving the request, the ORA PAM enters the reason for not initiating the inspection in Panorama, along with ORA's recommendation.
• ORA leads the inspection and CDER participates with appropriate (CDER and ORA management) concurrence.
• The inspection team reports its findings and provides recommendations via the ORA preapproval program manager (PAM) to OPF. All participants on the inspection team (CDER and ORA) are responsible for submitting their portion of the EIR and supporting exhibits to the lead investigator.
• OPF evaluates the inspection team's results within the context of the application and communicates relevant findings or concerns to the IQA team.
• For PAI withhold recommendations from ORA or significant deficiencies noted by OPF, OPF evaluates the inspection team's findings and the firm's response and makes the final recommendation on the adequacy of the firm for the covered PAI and application. OPF communicates the final recommendation (concurrence/nonconcurrence) to ORA.
For DFR requests:
• OPF requests a DFR through the OPF Decision/Request task.
• ORA has 10 business days to respond by entering approve facility, withhold approval, or PAI. The decision to initiate a PAI following a DFR is made in collaboration with OPF. When a PAI is indicated, the program management instructions above apply.
• For withhold recommendations, ORA communicates the rationale for the recommendation to OPF. OPF evaluates the rationale and makes the final recommendation regarding the firm's adequacy for the covered PAI and application. OPF communicates the final recommendation (concurrence/nonconcurrence) to ORA.
B. Scheduling and Preparation
A PAI should be requested and performed at the earliest opportunity, well before the user fee goal date. When scheduling the PAI, ORA should (1) consider the benefit to the application assessment process of resolving concerns observed during the PAI, and (2) allow sufficient time for the firm and applicant to addresses such concerns after the PAI.
A PAI may be scheduled with other inspection programs for efficient inspectional coverage. ORA division management may add a systems-based CGMP inspection pursuant to compliance program 7356.002 under specific circumstances, such as when:
• The establishment is on CDER's site surveillance inspection list from the risk-based site selection model. 17
• A for-cause inspection has been issued.
• Findings from the PAI indicate the need for coverage of marketed products.
ORA may choose to contact establishments before a PAI is conducted. If inspectional planning has started and the establishment is not ready for inspection, the establishment should provide a written explanation and the date when it will be available for inspection. 18
Any postponement of a scheduled inspection by the establishment or applicant should be reported to OPF promptly, as should any delays in gaining access to records or information that could affect FDA's time frames for assessing an application. 19 CDER should prepare for a PAI by conducting the following activities:
• The IQA project manager invites the ORA PAM, investigator, or division designee to participate in IQA meetings on the application.
• The OPF manufacturing assessor collects inspectional concerns from the IQA team and communicates these concerns to the ORA PAM and investigator in writing. The OPF manufacturing assessor provides insights and advice about covering these concerns on-site, which the investigator can use to develop an inspection plan.
Investigators should prepare for a PAI by conducting the following activities:
• Become familiar with the chemistry, manufacturing, and controls (CMC) section of the application and related drug master files (DMFs) for the establishment to be inspected. If possible, review the pharmaceutical development section before initiating the inspection.
• Participate as appropriate in IQA meetings to provide or seek feedback on the application. Also, as necessary, discuss questions/concerns related to data reliability ( 18 The written response should be from a responsible official at the facility or a designee. 19 Refer refusals of access to information to ORA's Office of Enforcement and Import Operations following existing procedures (e.g., Investigations Operations Manual).
data tables, raw material attributes, justifications for finished specifications) with the appropriate IQA team members. Determine if other IQA team members need data audit coverage of specific areas during the inspection.
• Contact the OPF manufacturing assessor with questions about the subject application when planning inspectional coverage. (This activity can be conducted by the ORA PAM, investigator, or a designee.)
• Develop an inspection plan with other inspection team members that is specific to the establishment and product being inspected and consistent with this program's objectives and inspectional and data auditing techniques. Review the history of the firm and Form FDA 483 observations from previous inspections.
Applications often contain trade secrets or confidential commercial information, and it is essential that the information be carefully protected to prevent its release outside FDA. Divisions are expected to establish a controlled access filing system to prevent the unauthorized use or release of application information.
C. Inspection Team
ORA leads PAIs for NDAs and ANDAs, and CDER participates with appropriate (CDER and ORA management) concurrence. ORA divisions assign experienced investigators and analysts, if needed, to conduct PAIs, and they may also request support directly from other offices, national expert investigators (drugs), or the Pharmaceutical Inspectorate. Support from such additional sources is especially valuable if local resource limitations affect a division's ability to perform the PAI. Team members conducting PAIs should have appropriate training and experience.
Importance of Application Assessment Integration
Achieving a science-based approval decision about each application from a pharmaceutical quality perspective requires an integrated assessment of the application and associated facilities. Because this requires input from multiple disciplines in FDA, differences of opinion may occur. FDA offices involved in the PAI program are covered by an equal voice philosophy. Under this philosophy, all appropriate expertise should be considered in the important decisions made about applications, and the perspective from each FDA office assigned a role in reviewing and evaluating drug applications is valuable. This equal voice environment is achieved, in practice, when each organizational unit:
• Integrates each contribution to enhance the decision of the multidisciplinary team.
• Provides an environment in which all team members can express their views for the areas in which they have a recognized responsibility.
• Ensures an avenue for promptly raising unresolved differences of opinion through the management chain for prompt resolution.
• Maintains transparency with a full and adequate record documenting decisions, including significantly differing views. The type and depth of inspectional/audit coverage needed to address each PAI objective is described in this section, along with appropriate regulatory citations.
A. Summary of Objectives
(1) Objective 1: Readiness for Commercial Manufacturing
Determine whether the establishment has a quality system that is designed to achieve sufficient control over the facility and commercial manufacturing operations. 20
• Objective 1a: Manufacturing and laboratory changes, deviations, and trends relating to the development of drug substance and drug product manufacturing have been adequately evaluated.
• Objective 1b: A sound and appropriate program for sampling, testing, and evaluating components (including active pharmaceutical ingredients (APIs)), in-process materials, finished products, containers, and closures for purposes of releasing materials or products has been established, including a robust supplier qualification program.
• Objective 1c: Sufficient facility and equipment controls are in place to prevent contamination of and by the application product (or API).
• Objective 1d: Adequate procedures exist for batch release, change control, and investigating failures, deviations, complaints, and adverse events, and for reporting this information to FDA (e.g., through FARs).
• Objective 1e: The proposed commercial process and manufacturing batch record, including instructions, processing parameters, and process control measures, are feasible and scientifically and objectively justified. This objective is linked to the firm's process validation program across the product lifecycle.
(2) Objective 2: Conformance to Application
Verify that the formulation, manufacturing or processing methods; analytical (or examination) methods; and batch records are consistent with descriptions contained in the CMC section of the application. This may include CMC information relevant to exhibit batches, biobatches, other pivotal clinical batches, and the proposed commercial-scale process.
(3) Objective 3: Data Integrity Audit
Audit and verify raw data at the facility that are associated with the product. This information can, among other things, help to authenticate the data submitted in the CMC section of the application as relevant, accurate, complete, and reliable for CDER assessment. 
(1) Objective 1: Readiness for Commercial Manufacturing
Determine whether the establishment has a quality system that is designed to achieve sufficient control over the facility and commercial manufacturing operations.
(a) Objective 1a: Manufacturing and laboratory changes, deviations, and trends relating to the development of drug substance and drug product manufacturing have been adequately evaluated.
Assess whether investigations relevant to the proposed commercial manufacturing process have been appropriately evaluated, including related laboratory, equipment maintenance, and manufacturing (e.g., development batch) investigations. Investigative reports or resultant change control reports for development issues may not always be as comprehensive as required for marketed drugs. Nonetheless, the firm should appropriately document, record, and objectively assess all development data and information, including but not limited to data submitted in or generated after the filing of an application or DMF. Examples of deviations related to the application include:
• Laboratory issues that occurred during or after method validation, such as:
o Unexpected laboratory events-including results that fall outside of the specifications or acceptance criteria-identified during stability, in-process, and release testing for the exhibit batches, biobatches, or process validation batches.
o Discrepancies found while conducting the method validation (particularly issues that may have occurred in its final stages) or technical transfer.
o Changes in an analytical method after completing the method validation or technical transfer because of an inability to use the method as written.
• Related equipment maintenance and performance issues, which could affect the proposed commercial manufacturing process, such as:
o Calibration failures associated with commercial equipment planned for use in the proposed commercial batch record.
o CGMP investigations and trending associated with the performance and capability of the commercial equipment planned for use in the proposed commercial batch record.
o CGMP manufacturing investigations (e.g., significant deviations, rejects, complaints/returns) and trending associated with similarly manufactured marketed drug products at the establishment.
o Significant equipment failures.
Evaluate these investigations to determine if the establishment is prepared for the proposed commercial manufacturing process at commercial scale, including that there are appropriate controls in place to detect and mitigate the most likely and significant problems. Review sampling plans and procedures, including those described in batch records, to evaluate the establishment's intended approach to sampling components, in-process materials, and finished product. Sampling plans must ensure that representative samples are collected and tested/examined as verification of product quality. The method of selecting samples, number of samples taken, statistical criteria for the number of samples taken, and acceptable and unacceptable quality limits should be scientifically based and appropriate. Consider the extent of experiences with the proposed commercial process when determining adequacy of sampling plans. Also, areas of criticality or process vulnerability should receive special attention because these points in a process generally require more extensive sampling. For example, a firm may consider the use of process analytical technology (PAT (3)). 23 Refer to compliance program 7356.002F-Active Pharmaceutical Ingredient (API) Process Inspection. and packaging materials. ICH Q7, section VII.C, Sampling and Testing of Incoming Production Materials, recommends that samples should be representative of the batch of material from which they are taken. ICH Q7, section XI.F, Expiry and Retest Dating, addresses sampling in the context of performing a retest.
(c) Objective 1c: Sufficient facility and equipment controls are in place to prevent contamination of and by the application product (or API).
Coverage of this element is warranted for new construction or facility design, new uses of existing equipment that pose potential risks (e.g., addition of a highly potent product), or equipment operations unique to the application under review. Observe the firm's operations as you inspect the facility and after reviewing blueprints, floor plans, or as-built diagrams of utility systems (such as the purified water system piping and air handling systems). Verify that the establishment has facility, equipment cleaning, maintenance, and utility system controls in place (or planned) that are designed to prevent contamination that could be deleterious to the specific application product, and ensure that controls are in place to prevent cross-contamination of and by the application product.
Inspect new construction intended for the application product, as well as the installation of new equipment, and other significant changes to the existing facility or practices relating to material/personnel flow. Evaluate the establishment's proposed compliance with related CGMP requirements. Pay special attention to the new product or marketed products that are highly potent or potentially sensitizing in humans to ensure that the product is not liable to contaminate existing products in the facility.
Related regulations for finished pharmaceuticals: 21 CFR 211.42-211.67 require facility and equipment controls to prevent contamination and to ensure well-organized operations.
Related guidance for APIs: Refer to ICH Q7, sections IV.A (Design and Construction) through V.B (Equipment Maintenance and Cleaning), which recommend facility and equipment controls to prevent contamination and to ensure well-organized operations.
(d) Objective 1d: Adequate procedures exist for batch release, change control, and investigating failures, deviations, complaints, and adverse events, and for reporting this information to FDA (e.g., through FARs).
Review the establishment's quality and change procedures and audit the establishment's compliance to its procedures for already marketed product, as appropriate (e.g., selecting actual failures, deviations, and complaint investigations; related adverse drug experience reports, including submissions to FDA if required). Note that the regulations for adverse drug experience (ADE) reporting only cover prescription and application products. If significant problems are found with the establishment's existing complaint handling and reporting procedures, the division should consider recommending a directed inspection of the (e) Objective 1e: The proposed commercial process and manufacturing batch record, including instructions, processing parameters, and process control measures, are feasible and scientifically and objectively justified. This objective is linked to the firm's process validation program across the product lifecycle.
An essential part of the inspection is evaluating the justification for the proposed commercial process and the manufacturing batch record. The extent of process validation activities that have been completed at the time of application submission can vary, but, at a minimum, data from Stage I process validation should be available. To establish process feasibility, evaluate Stage I process validation development studies and knowledge gained about manufacturing operation vulnerabilities, including the influence of raw material variability, and determine the purpose of each study performed by the firm. For example, review studies conducted to establish process controls or process parameters directly related to the CQAs of the drug product in the application. 25 These may include studies of worst-case or boundary conditions to establish proven acceptable ranges or more sophisticated studies involving design of experiment or multivariate analysis modeling. Assess the protocols and their execution and the reliability of the data and conclusions. Include the inadequacy of data to support the filed processing approach, or the proposed master batch record provided during inspection, on Form FDA 483.
This evaluation includes a review of the firm's scale-up studies (e.g., the scale-up from the biobatch, or pivotal batches, to a larger (interim or full) scale batch). The firm may need to change its proposed commercial process as scale-up studies are completed and knowledge is gained. Such changes alone are not a violation and should not be cited as a deficiency. However, if feasible, discuss these findings with the OPF manufacturing assessor to determine the impact of such changes on the objectives of this compliance program.
Determine and report the firm's projected timeline for completion of additional process validation activities and additional planned studies and their purpose. Though not required at the time of the PAI, completion of certain planned studies, including Stage 2 of process validation, 26 may demonstrate that the product can be reliably manufactured at commercial scale. If the firm states that it has completed the process validation activities necessary to distribute the finished drug product (i.e., completion of Stage 2, Process Performance Qualification), fully audit and assess these studies and conclusions. These include studies and experiments to scientifically optimize processing parameters and other manufacturing instructions for significant processing steps. Additional studies typically include commercial-scale batches (conformance batches) that are manufactured at the site in accordance with the master batch and production control record using qualified commercial-scale equipment and utilities and trained production personnel. These commercial-scale studies are typically conducted in accordance with a formal protocol and are intended to confirm the process design before commercial launch. They also establish a level of reproducibility and consistency at nominal processing conditions. One of the firm's conclusions from these Stage 2 process validation studies must be that a high level of assurance was achieved in that the commercial process is capable of consistently delivering quality product meeting its CQAs. Though not required at the time of the PAI, the manufacturer is expected to plan for sufficient ongoing evaluation (Stage 3, Continued Process Verification) of the manufacturing process once marketing approval has been granted by CDER.
Thoroughly examine results and data of manufactured batches to determine if unresolved issues exist with the commercial control strategy. Listed below are examples of situations requiring follow-up:
• The drug product or API does not meet its CQAs, and root cause has not been determined.
• Batch records, in-process data, or process monitoring records reveal an unexpected highly variable process and the reason is unknown.
• Inconsistent execution of the batch record and manufacturing instructions or operator workarounds (possible indication of poor process design or training).
• Control measures do not appear to align with raw development data (e.g., important parameters or material attributes that impact CQAs are not being monitored or measured at the appropriate frequency).
• Sampling and monitoring plans for Stage 2 process validation (e.g., process qualification) are not justified or are insufficient based on raw development data.
• The data justifying critical process parameters are inadequate.
Review completed studies in the process validation lifecycle for related drugs to evaluate the firm's capabilities and procedures. Interviewing key employees, such as the lead validation engineer, may be helpful in assessing a firm's ability to implement a sound process and control strategy. List deficiencies in these studies on Form FDA 483, and advise the firm that appropriate corrections must be completed before commercial distribution of the first batch.
If unable to provide sufficient process validation lifecycle coverage, state as such in the inspection report. Divisions should cover these processes during the next surveillance or postapproval inspection.
ORA and CDER review of information may overlap because applicants are being encouraged to share more product and process development information with CDER in accordance with FDA guidance. 27 The investigator should incorporate CDER insights into the inspectional evaluation of the proposed commercial process and should discuss inspectional findings regarding the adequacy of the establishment's Stage 2 process validation plans (i.e., process performance qualification plans) with OPF. The investigator should discuss process performance qualification plan issues with the firm, OPQ requires that certain data be filed to demonstrate that aseptic filling and sterilization processes are validated before approval is granted. OPF's review of this summary information is complemented by FDA's on-site inspection of these operations. Evaluating the adequacy of process validation at a facility is critical to ensure implementation of reproducible processes.
The investigator may find that the inspected establishment was not responsible for performing some of the process development activities and studies, and that reports for development studies are not available for inspection. The investigator should collect information about each establishment involved in process development (e.g., name, address, responsible person, work performed). This information should be included in the EIR. The OPF manufacturing assessor will then determine if additional facilities need to be evaluated or inspected.
Related regulations for finished pharmaceuticals: 21 CFR 211.100(a) and 211.110 require developing a well-designed and reproducible process, and 21 CFR 211.22 covers the quality unit's responsibilities. Aseptic and sterilization processes are required to be validated by 21 CFR 211.113(b) and 211.42.
Related guidance for APIs: Refer to ICH Q7, sections XII.A (Validation Policy) through XII.E (Process Validation Program) for guidance regarding process validation.
(2) Objective 2: Conformance to Application
To address this objective, conduct the following activities:
• Observe the processing lines, unit operations-both scale and type (including aseptic or sterilization processes)-and laboratory methods and compare with the description and/or batch records submitted in the CMC section of the application (or DMF).
• Audit the detailed manufacturing records and ensure their consistency with the general description of the processing methods described in the application. Review the biobatch and other pivotal batches and compare them with the commercial-scale process. Compare actual manufacturing records (e.g., pivotal clinical lots, biobatches, exhibit batches) to the production method described in the application and contact OPF if significant differences are observed. It is also important to ensure that batches placed on stability for expiration date (or retest date) determination are representative of the proposed marketed product.
• Verify that the biobatch, registration/exhibit, and stability batch sizes are as reported in the CMC section. For biobatches, or pivotal clinical batches, FDA might not always visit the manufacturing establishment. However, it is important to make every effort to evaluate the records associated with the batches and understand their manufacturing context.
Inspectional coverage of analytical methods validation for tests described in the application should include methods for testing the components, in-process materials, and finished product. Compare the methods filed with the methods in use in the facility. Review the validation data and reports for each test method to ensure that there are no significant variations from the filed method and specifications.
• Inspect the actual performance of the methods during the PAI, including laboratory deviations, trends, and other indications of a lack of method reliability. Not all methods need to be covered during the PAI. Coverage should be given particularly to methods/testing that are unique to the product application under inspection, technically complicated to perform, or measure a high-risk CQA. Consultation with the IQA team may be useful in identifying such methods.
• Audit all the records associated with the sample if an inspected establishment sent samples to FDA for analysis (as described below and in Part IV of this compliance program).
• Report as soon as possible any finding that casts doubt on the authenticity of a biobatch or whether any samples from the biobatch provided to FDA may not actually be from the biobatch specified in the application (as filed in the CMC section). Records that are considered good candidates for audit include shipping records, equipment use logs, inventory records, analytical testing results, and related research/scale-up batch records.
• Examine raw data and test records and compare them with submitted data for components used in the biobatch and finished product and records associated with biobatch production. Consultation with the CDER application assessors in advance of the inspection is essential to learn which component attributes, finished product specifications, and processing methods are critical to establishing the comparability of the biobatch and proposed commercial process.
• Inspect laboratory methods and audit research and development notebooks. Review of inventory or receiving records of APIs as well as other components is a way of verifying and evaluating the context and integrity of batch information submitted in applications.
• Verify that the API manufacturer is the same as reported in the CMC section and ensure that no other records indicate a different API manufacturer or API quality from that described in the application. If the application submission is for an API manufacturer other than the primary supplier, audit the data demonstrating the comparability (e.g., impurity profiles, physical characteristics), including quality, of the new API manufacturer with the previous manufacturer.
Conformance to the application under this objective may be relevant to Objective 3, Data Integrity Audit. This typically involves verification of the factual integrity of the information filed in the application and the contextual integrity of information supporting that filed information. 28
28 Information that has factual integrity is original and corresponds directly to that submitted to FDA (e.g., a chromatogram showing a peak area that directly calculates to an assay value submitted in a data summary sheet in the application). Information that has contextual integrity supports submitted information about the testing or manufacturing area and related products/processes (e.g., a chromatographic sequence that shows all the assayed samples and that does not reveal failing assay values). Missing records (batch or testing) and unexplained losses of inventory of components used in production may call into question the contextual integrity of the information filed in an application. 
(3) Objective 3: Data Integrity Audit
Audit and verify raw data at the facility that are associated with the product. This information can, among other things, help to authenticate the data submitted in the CMC section of the application as relevant, accurate, complete, and reliable for CDER assessment.
Audit the accuracy and completeness of data reported by the facility for the product. Not every CMC data summary must be audited to accomplish this objective. The inspectional strategy may select key data sets from drug development (e.g., formulation development, Stage 1 of process validation) or randomly select data filed in the application. Generally, data on finished product stability, dissolution, content uniformity, and API impurity are good candidates for this audit.
In addition to summary tables, applicants typically submit additional testing for the finished product's performance and physicochemical attributes. During the inspection, compare raw data-hardcopy or electronic-such as chromatograms, spectrograms, laboratory analyst notebooks, and additional information from the laboratory with summary data filed in the CMC section. Raw data files should support a conclusion that the data/information reported by the site are complete and accurate. Examples of data integrity concerns include failure to scientifically justify not reporting relevant data, such as aberrant test results or absences in a submitted chromatographic sequence.
When data discrepancies are observed, identify firm personnel involved. Determine which actions or inactions contributed to the data integrity problem and whether corrective actions were or are to be taken. Also determine whether data that should have been reported in the application were not reported. For example, did the firm:
• Substitute passing data (i.e., within specification or otherwise favorable) for failing data (i.e., out of specification or unfavorable) without a sufficient investigation and resolution of the discrepancy?
• Improperly invalidate out-of-specification results?
Following are possible indications of data integrity problems:
• Alteration of raw, original data and records (e.g., the use of correction fluid). • Records, reports, or information referring to failing biostudies.
• Discrepancies (e.g., color, shape, embossing) between material used in a biostudy and reserve samples.
• Inconsistencies in manufacturing documentation (e.g., identification of actual equipment used) and other information in the submission.
• Multiple analyses of assay using the same sample without adequate justification.
• Exclusion of specific lots from the stability program to avoid submitting failed results.
• Reworking or process modifications not adequately justified or appropriately reported.
• Manipulation of a poorly defined analytical procedure and associated data analysis to obtain passing results.
• Backdating stability test results to meet required commitments.
• Fabrication of acceptable test results without performing the test.
• Use of test results from previous batches to substitute testing for another batch.
• The site does not actually manufacture the drug as described in the drug application or the DMFs referenced therein. 29
The investigators should clearly indicate in the EIR whether their findings call into question the reliability of the submitted data. Specific data/information filed in the application should be referenced, when possible. It is essential that the ORA division notify OPF of data reliability concerns promptly to trigger an immediate evaluation of the impact on the application. If such situations are observed, thoroughly document the unreliable data (see III.2.B, Completion of the Establishment Inspection Report).
If a pattern of data reliability issues is identified during a PAI, the investigator should consider expanding the coverage to surveillance of marketed products manufactured in the facility using compliance program 7356.002. If data reliability issues are documented for other products during an expanded inspection, this suggests a broader pattern that implicates all products manufactured at the facility. If so, ORA should consider submitting a recommendation that CDER consider invoking the Application Integrity Policy (AIP) or that a for-cause inspection be planned to further define the scope of the data reliability issues. 
C. Investigator Questions and Concerns During an Inspection
Following the principles of ICH Q7, Q8, Q9, Q10, and Q11, 31 FDA is implementing a more integrated approach towards preparing for and conducting inspections. CDER and ORA will collaborate to provide an efficient and effective use of inspectional resources. Each deficiency identified by the CDER inspection participant should be discussed with the lead investigator to clarify follow-up activities and responsibilities. Questions that arise during an inspection should normally be directed to the assigned OPF manufacturing assessor and ORA PAM. Questions and concerns may, for example, relate to facility control, process control, batch release, quality assurance, manufacturing procedures, product development summaries, product attributes, or test methods. The assigned OPF manufacturing assessors for a given application are listed in Panorama.
NDA/ANDA Inspection Reporting
A. Issuance of Form FDA 483
Reportable observations from the inspection will be issued to the establishment on Form FDA 483, consistent with instructions in the Investigations Operations Manual (IOM). 32 Significant CGMP deficiencies pertaining to the PAI products and significant instances of application nonconformances should be cited on Form FDA 483. If the inspection is a concurrent CGMP inspection and PAI, organize Form FDA 483 according to compliance program 7356.002 and the IOM. 33 The following are examples of PAI findings that can potentially impact product quality and should appear on Form FDA 483:
• PAI findings that differ from the filed CMC description of the process for the biobatch, or stability batches; the lack of an adequate or sufficiently specific proposed commercial batch record to provide for a reproducible manufacturing operation; or inadequate procedures or instructions for controlling the process or equipment intended to support commercial operation.
• PAI findings that differ from the filed CMC description of formulations, processing principles, equipment used, or discrepancies in raw material lot reconciliation (inconsistencies in firm's records for receipt, inventory, or use in production).
• Missing data or unreliable data:
o Data/information submitted to the application that were potentially unreliable or misleading and the relevance of these data/information. o Unexplained or inappropriate gaps in a chromatographic or analytical sequence.
• A pattern of inappropriately disregarding test results.
• Inadequate or lack of justification for not reporting data/information.
• Insufficiency, discrepancy, or failure of an analytical method validation program.
• Lack of suitability of the facility, equipment, or manufacturing operations intended for making the commercial API or finished product to the CGMP regulations.
• Other specific nonconformance (e.g., conditions, practices, procedures) to the CGMP regulations.
B. Completion of the Establishment Inspection Report
The inspection team prepares a narrative EIR per instructions in the IOM (Chapter 5). The EIR should be completed as follows:
• Organize the EIR's Manufacturing/Design Operations section by the PAI objectives (as described in Part II of this compliance program).
• Briefly describe the responsibilities of the inspected firm in relation to the assigned application.
• Describe the manufacturing operations and summarize coverage provided during the inspection as described in this compliance program.
• Address application-related inspectional concerns communicated by the IQA team with specific data, areas covered, citations, and discussion with management.
If the inspection is a concurrent CGMP inspection and PAI, the EIR should be organized according to compliance program 7356.002.
Sample Collection or Sample Submission Requests
Investigators should not collect samples during the PAI unless requested as a part of the inspection assignment by CDER or on a for-cause basis. Investigators may collect samples only after getting approval from their ORA PAM or supervisor and notifying OPF and the relevant IQA team assessor. OPF checks with other program coordinators to verify that samples have not already been collected and can be analyzed. 
PART IV-ANALYTICAL
For NDAs and ANDAs pending a regulatory decision, drug product samples and test methods can be collected to:
• Verify whether the firm's test methods are suitable for regulatory use and whether the drug product meets compendial or the firm's specifications.
• Verify the integrity of the bioequivalence study.
• Authenticate the proposed drug product (e.g., new, generic).
• Provide a reference standard for postmarketing surveillance.
Attachment C provides an example of sample and record collection instructions for solid oral dosage finished product manufacturers.
OPQ/OTR/DPA as well as ORA laboratories perform testing on samples collected. The analyzing laboratory (OPQ/OTR/DPA or ORA/ORS) maintains completed analytical worksheets. OPQ/OTR/DPA enters the laboratory results for method verification samples 35 for an NDA or ANDA into Panorama. The analyzing laboratory forwards a copy of the laboratory results to the CDER or ORA office that requested or collected samples.
The analyzing laboratory reports adverse findings by emailing a copy of the worksheet to the following recipients:
• Drug substance assessor or drug product assessor assigned to the submission.
If warranted, ORA division offices may recommend an appropriate regulatory action to CDER.
35 See note 34.
PART V-REGULATORY/ADMINISTRATIVE STRATEGY
ORA Recommendations
ORA divisions either inspect the establishment named in an application or they perform a file review and provide a recommendation for the facility's acceptability. Based on the outcome of the PAI, the ORA PAM uses Panorama to make an approve or a withhold recommendation.
A. Approve Recommendation
The ORA PAM makes an approve recommendation if there are no significant issues that would adversely impact the establishment's ability to perform its designated functions described in the application.
B. Withhold Recommendation
The ORA PAM makes a withhold recommendation if there are significant issues that would adversely impact the establishment's ability to perform its designated functions described in the application. For example:
1) Significant data integrity problems, including misrepresented data or other conditions related to the submission batches.
2) Serious CGMP concerns with the manufacture of a biobatch or pivotal clinical, exhibit, or validation batches such as changes to formulation or processing.
3) Significant differences between the process used for pivotal clinical batches or biobatches and application exhibit batches.
4)
Lack of complete manufacturing and control instructions in the master production record or lack of data to support those instructions. 5) Lack of capacity to manufacture the drug product or API. (If the firm is not ready for an inspection, the division should request a letter from the establishment.) 6) Failure to meet application commitments (e.g., the firm is not performing functions as listed or described in the application).
7)
Full-scale process performance qualification studies attempted and failed before the PAI, which demonstrate that the process is not under control and the establishment is not making appropriate changes. 8) For products for which full-scale summary information is provided in the application, no demonstration that the product (1) can be reliably manufactured at commercial scale or (2) can meet its CQAs. 9) Incomplete or unsuccessful analytical method validation or verification. 
Additional Considerations
If the ORA division recommends withhold for an application because of deficiencies and findings for inspectional coverage under compliance program 7356.002, the division enters a potential official action indicated (pOAI) alert in Panorama and considers recommending an advisory or enforcement action. The Office of Compliance reviews ORA's recommendation for appropriate action if necessary.
OPF reviews the PAI results (EIRs, Form FDA 483s, firm responses, ORA division evaluation of the firm responses) when ORA divisions recommend withhold and provides a recommendation in Panorama. OPF updates the final decision and profiles (as appropriate) in eNSpect and shares the review of the EIR, facility recommendation, and impact on the regulatory action with the IQA team. In addition, OPF will update the Compliance Management System (CMS) with information pertinent to the review.
Should additional information (e.g., firm response or its evaluation by the ORA division) become available within a reasonable time frame before the OPQ application action date, OPF may update its assessment and facility recommendation. Alternatively, OPF may defer further assessment to the next assessment cycle for the subject application. An OPF decision to recommend facility approval depends on satisfactory correction of the findings that led to the initial withhold recommendation. OPF and ORA may confirm satisfactory corrective action using a follow-up inspection.
When the ORA division recommends withhold for a PAI of an establishment that does not market FDA regulated products, a warning letter is not usually the appropriate regulatory action. However, if objectionable findings are observed and the findings affect marketed drugs, refer to the drug manufacturing inspection compliance program 7356.002.
Exception to withhold recommendation: ORA divisions will not recommend withholding approval of NDAs and ANDAs solely for a lack of complete commercial-scale process validation at the time of a PAI (see also guidance for industry Process Validation: General Principles and Practices and CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval 37 ). Although sufficient process validation studies may not have been completed at the time of the PAI to release the product, the firm must achieve a high degree of assurance that the manufacturing process consistently produces a product that meets its quality attributes before distribution. 36 
ATTACHMENT A: CDER-ORA COLLABORATION FOR ENSURING PRODUCT QUALITY
In the ConOps framework, preapproval inspections (PAIs) are integrated with application assessments to help identify and resolve product quality issues. 38 This integrated approach generally involves the following activities:
• IQA team assessment before the PAI, during which the integrated quality assessment (IQA) team assesses the application risks to product quality that could impact safety and efficacy, including bioequivalence, and recommends whether a PAI is needed. If a PAI is needed, the IQA team communicates risks and concerns regarding the quality of the product, process, and facility to the inspection team.
• PAI, during which the inspection team performs the on-site inspection for the specified application(s) in accordance with the objectives of this compliance program and current good manufacturing practice (CGMP), discusses inspection findings, and, if warranted, lists significant deficiencies on Form FDA 483, which is issued to the inspected facility.
The facility provides responses to the issued Form FDA 483, including proposed corrective and preventive actions, if required, to the Office of Regulatory Affairs (ORA).
• IQA team assessment after the PAI, during which:
o ORA provides the IQA team with the firm's responses, including the proposed corrective and preventive actions and its initial facility recommendation. The IQA team works with other disciplines, as appropriate, to assess information relevant to novel excipients and determines the risks and concerns pertaining to the quality of the novel excipient.
Novel excipient manufacturers are not routinely inspected, unless specifically requested by the IQA team.
The inspection team evaluates the excipient facility for conformance with CGMPs, such as the adequacy of the supplier's qualifications, ongoing QC testing regimen, and storage/handling practices and procedures.
The inspection team evaluates the on-site mitigation strategy and controls for the risks and concerns identified by the IQA team.
ORA provides the IQA team with its initial facility recommendation.
The IQA team assesses the inspection findings and their impact on application approval.
CDER, on behalf of the IQA team, may communicate with the applicant, DMF holder, or inspected facility, as appropriate, to resolve outstanding quality issues.
The IQA team, which may consult with other CDER staff, may use findings of substandard excipients to request that the applicant update the application, for example, with revised excipient specifications.
Application approval by CDER includes appropriate controls for excipient quality.
For example:
The IQA team recommends a PAI of the excipient manufacturing facility to better assess identified excipient risks and communicates the risks and concerns to the inspection team.
The inspection team finds that released excipient lots do not meet the excipient manufacturer's specifications and includes its observations on Form FDA 483.
The IQA team communicates excipient quality concerns with the inspected facility and applicant and requests that the applicant update the application with revised excipient specifications. The IQA team may communicate to the inspection team specific risks or concerns about the quality of raw materials and components (e.g., APIs, excipients) with characteristics controlling or contributing to drug product CQAs.
The IQA team reviews raw material controls, such as specifications for adequacy and appropriateness.
The inspection team evaluates the adequacy of the supplier's qualifications, ongoing QC testing, laboratory controls, storage/handling, and sampling procedures in accordance with CGMPs.
The IQA team assesses the inspection findings and their impact on component quality to make the quality recommendation.
CDER, on behalf of the IQA team, may communicate with and request that the applicant, component's DMF holder, or inspected facility make appropriate changes to resolve outstanding issues with the quality of components.
Application approval by CDER includes appropriate raw material controls.
The IQA team identifies a risk associated with a component critical to drug product CQAs and asks the inspection team to verify component quality and evaluate the supplier qualification program at the facility.
The inspection team finds that the specifications in the supplier's COA and in the application do not match (e.g., supplier specifications are wider than indicated in the application), the component supplier's COA is not periodically verified, and the supplier is not reliable. The IQA team assesses test methods and acceptance criteria for the finished drug product submitted in the application.
The inspection team evaluates the integrity of test data submitted in the application and reports questionable data to the IQA team.
The inspection team assesses whether the test method has been verified to operate under specified conditions of use.
The IQA team assesses the inspection findings to make the quality recommendation.
Application approval by CDER includes approval of the drug product control strategy, including finished product testing and acceptance criteria.
The IQA team communicates to the inspection team specific risks and concerns regarding test methods (e.g., suitability and validation data) and acceptance criteria (e.g., adequacy and verification of submitted data).
The inspection team finds dissolution data that were not submitted to the application and includes its observations on Form FDA 483.
The IQA team, which is responsible for recommending approval of the dissolution specification, uses the findings about the additional data to request that the applicant update the application with a revised dissolution specification. The IQA team assesses the process design's overall development, including a review of manufactured batches (e.g., biobatch; pilotscale, exhibit, or commercialscale batch), proposed commercial manufacturing information, and available test data. The IQA team also determines if differences between pilot-and commercial-scale batch processes could adversely impact product quality.
The IQA team communicates to the inspection team risks and concerns relevant to product/process development and commercial scale-up challenges.
Product/process development facilities are not routinely inspected, unless specifically requested by the IQA team.
The inspection team evaluates the facility for conformance with CGMPs, the objectives of this compliance program, and the risks and concerns identified by the IQA team.
The inspection team compares the firm's development and scale-up studies (e.g., scale-up from the biobatch, or pivotal batches, to a larger interim or full-scale batch) with the proposed commercial process and reports significant manufacturing process changes (including control strategy) and differences in equipment operating principles.
The IQA team assesses the inspection findings and their impact on the drug product control strategy to make the quality recommendation.
If the inspection findings indicate differences between pilot-scale and proposed commercial-scale manufacturing that could adversely impact product quality, CDER, on behalf of the IQA team, may communicate with the applicant or inspected facility, as appropriate.
The IQA team may request that the applicant perform additional studies to support the application and the proposed control strategy at the commercial site.
The IQA team requests inspection of any facility involved in the development of the drug product, including exhibit batches, if it differs from the commercial facility.
The inspection team finds that exhibit batches were not manufactured under CGMP or as indicated in the application, which raises a concern about product quality. The inspection team includes its observations on Form FDA 483.
The IQA team uses the finding of differences between pilot-and commercial-scale batch manufacturing methods to request that the applicant update the application with study data to ensure drug quality for the commercialscale batches.
